BioCentury | Jun 19, 2019
Clinical News

June 19 Clinical Quick Takes: G1 jumps on breast cancer data; plus Linzess, Lokelma, Boehringer/OSE, GCAR and more

..."Boehringer In-licenses Anti-SIRPA Checkpoint Inhibitor" ). GCAR begins world's first GBM adaptive clinical trial The Global Coalition for Adaptive Research...
...BAY 73-4506, DAST Inhibitor) trilaciclib (G1T28, iv g1t28-1) zanubrutinib (BGB-3111) Allergan plc AstraZeneca plc Bayer AG BeiGene Ltd. Boehringer Ingelheim GmbH G1 Therapeutics Inc. Global Coalition for Adaptive Research Ironwood...
BioCentury | Mar 23, 2019
Tools & Techniques

A frequentist and a Bayesian walk into a trial

...evidence that will help us to improve the way we write regulatory policy.” I-SPY, the Global Coalition for Adaptive Research...
...Germany Eli Lilly and Co. (NYSE:LLY), Indianapolis, Ind. European Medicines Agency (EMA), Amsterdam, The Netherlands Global Coalition for Adaptive Research...
BioCentury | Nov 16, 2018
Clinical News

Bayer's Stivarga first to enter adaptive brain cancer trial

...Bayer AG (Xetra:BAYN) and the Global Coalition for Adaptive Research (GCAR) said Stivarga regorafenib will be the first therapy to...
...hepatocellular carcinoma (HCC). It is a dual acting signal transduction (DAST) inhibitor of multiple kinases. Global Coalition for Adaptive Research...
BioCentury | Nov 14, 2018
Clinical News

Bayer's Stivarga first to enter adaptive brain cancer trial

...Bayer AG (Xetra:BAYN) and the Global Coalition for Adaptive Research (GCAR) said Stivarga regorafenib will be the first therapy to...
...DAST) inhibitor of multiple kinases. Jennie Walters Stivarga, fluoro-sorafenib, regorafenib (BAY 73-4506, DAST Inhibitor) Bayer AG Cure Brain Cancer Foundation Global Coalition for Adaptive Research National...
Items per page:
1 - 4 of 4
BioCentury | Jun 19, 2019
Clinical News

June 19 Clinical Quick Takes: G1 jumps on breast cancer data; plus Linzess, Lokelma, Boehringer/OSE, GCAR and more

..."Boehringer In-licenses Anti-SIRPA Checkpoint Inhibitor" ). GCAR begins world's first GBM adaptive clinical trial The Global Coalition for Adaptive Research...
...BAY 73-4506, DAST Inhibitor) trilaciclib (G1T28, iv g1t28-1) zanubrutinib (BGB-3111) Allergan plc AstraZeneca plc Bayer AG BeiGene Ltd. Boehringer Ingelheim GmbH G1 Therapeutics Inc. Global Coalition for Adaptive Research Ironwood...
BioCentury | Mar 23, 2019
Tools & Techniques

A frequentist and a Bayesian walk into a trial

...evidence that will help us to improve the way we write regulatory policy.” I-SPY, the Global Coalition for Adaptive Research...
...Germany Eli Lilly and Co. (NYSE:LLY), Indianapolis, Ind. European Medicines Agency (EMA), Amsterdam, The Netherlands Global Coalition for Adaptive Research...
BioCentury | Nov 16, 2018
Clinical News

Bayer's Stivarga first to enter adaptive brain cancer trial

...Bayer AG (Xetra:BAYN) and the Global Coalition for Adaptive Research (GCAR) said Stivarga regorafenib will be the first therapy to...
...hepatocellular carcinoma (HCC). It is a dual acting signal transduction (DAST) inhibitor of multiple kinases. Global Coalition for Adaptive Research...
BioCentury | Nov 14, 2018
Clinical News

Bayer's Stivarga first to enter adaptive brain cancer trial

...Bayer AG (Xetra:BAYN) and the Global Coalition for Adaptive Research (GCAR) said Stivarga regorafenib will be the first therapy to...
...DAST) inhibitor of multiple kinases. Jennie Walters Stivarga, fluoro-sorafenib, regorafenib (BAY 73-4506, DAST Inhibitor) Bayer AG Cure Brain Cancer Foundation Global Coalition for Adaptive Research National...
Items per page:
1 - 4 of 4